Novartis Avidity siRNA DMD Myotonic Dystrophy — PatSnap Eureka
Novartis–Avidity: Muscle-Targeted siRNA for DMD & Myotonic Dystrophy
The Avidity acquisition places the anti-TfR1 antibody–oligonucleotide conjugate (AOC) platform — with clinical programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 — at the center of Novartis's RNA therapeutics strategy. Explore the patent signals, molecular targets, and competitive dynamics driving this deal.
Two Neuromuscular Diseases, One Delivery Platform
The Novartis–Avidity acquisition is anchored in two distinct but mechanistically related neuromuscular diseases. Duchenne Muscular Dystrophy (DMD) is an X-linked recessive disorder caused by loss-of-function mutations in the DMD gene encoding dystrophin — the largest gene in the human genome. Retrieved patent literature describes therapeutic strategies centered on restoring a truncated but functional dystrophin via exon skipping, particularly targeting exons 44, 45, 50, 51, and 53 within the dystrophin pre-mRNA. The PatSnap life sciences platform tracks over 500 active DMD-related patent families globally.
Myotonic Dystrophy Type 1 (DM1) is caused by a CTG trinucleotide repeat expansion in the 3′ untranslated region of the DMPK gene. Expanded CUG repeat RNA transcripts sequester the splicing regulator MBNL1 (muscleblind-like protein 1) in nuclear foci, causing widespread alternative splicing dysregulation. The primary therapeutic target in this dataset is DMPK mRNA silencing via RNAi — intended to reduce toxic RNA foci and liberate MBNL1 for normal splicing activity. Research from NIH-funded investigators including Charles Thornton (University of Rochester) has established MBNL1-dependent splicing correction as the key pharmacodynamic endpoint.
Both diseases converge on a shared delivery challenge: achieving sufficient oligonucleotide exposure in skeletal and cardiac muscle tissue. This is the core problem the anti-TfR1 AOC platform is designed to solve, as described in Avidity's foundational patent filings analyzed through PatSnap's IP analytics tools.
AOC Platform: Key Data Signals from Patent & Literature Analysis
All data derived from targeted patent and literature searches via PatSnap Eureka. Figures represent signals within the retrieved dataset only.
AOC vs. Unconjugated siRNA: Muscle Accumulation Advantage
Anti-TfR1 AOCs achieve 10–50-fold greater muscle accumulation vs. unconjugated siRNA in rodent and primate studies (Bhatt et al., 2023).
Avidity Biosciences AOC Patent Filing Activity (2021–2023)
Patent filing cadence across TfR1 delivery, DMPK silencing, exon skipping, and combination approaches reflects accelerating IP prosecution ahead of clinical milestones.
DMPK mRNA Knockdown in DM1 Mouse Models
Optimized siRNA with 2′-O-methyl and phosphorothioate modifications achieve >80% DMPK mRNA reduction at AOC-deliverable doses (Avidity, US20230235340A1).
AOC Platform: Payload Modality Coverage by Disease Target
The anti-TfR1 AOC architecture is modality-agnostic — patent filings show application to siRNA, ASO, and dual-payload configurations across DMD and DM1 targets.
AOC Architecture: From Antibody Arm to RISC Silencing
Retrieved patent and literature signals characterize three therapeutic modality categories active in this disease space, with AOC as the dominant platform in the Avidity dataset.
Antibody–Oligonucleotide Conjugates (AOCs)
The dominant modality in the retrieved dataset. Monoclonal antibody or fragment targeting TfR1 is conjugated to a chemically modified siRNA or ASO via a cleavable or stable linker. Following receptor-mediated endocytosis, the siRNA payload is loaded into RISC, directing Ago2-mediated cleavage of target mRNA. Patent filings from Avidity describe monovalent and bivalent anti-TfR1 antibody formats with Fc-silencing LALA-PG mutations to prevent complement activation and ADCC in muscle tissue. Pharmacokinetic profiling in cynomolgus macaques demonstrates muscle-selective biodistribution. The PatSnap life sciences database tracks this entire patent family.
AOC 1001 (DM1) · AOC 1044 (DMD) — Phase 1/2Antisense Oligonucleotides (ASOs) — Reference Benchmark
Retrieved results describe ASO-based approaches in DMD — particularly phosphorodiamidate morpholino oligomers (PMOs) targeting exon 51 splice donor/acceptor sites — as a reference modality against which AOC delivery efficiency is benchmarked. Research from Leiden University Medical Center (Aartsma-Rus et al., 2021) notes that poor biodistribution of naked oligonucleotides to muscle remains the key limitation addressed by conjugate approaches. PMO-based drugs (eteplirsen, golodirsen, viltolarsen) show limited cardiac delivery — a gap the AOC platform targets. According to FDA records, three PMO-based exon skipping drugs are currently approved for DMD.
PMO exon 51 skipping — limited cardiac biodistributionSmall Molecule Splicing Modulators
A smaller subset of retrieved results references small molecule splicing modulators — including MBNL1-CUG repeat disruptors — in the DM1 context. These appear primarily as combination partners or competitive benchmarks rather than as the primary Avidity/Novartis modality. Their inclusion in the dataset signals awareness of a multi-modal therapeutic landscape in DM1, where RNA-level and protein-level interventions may be complementary.
MBNL1-CUG disruptors — combination potential in DM1Dual-Payload AOCs & Non-TfR1 Receptor Arms
Patent filings from Avidity (2022–2023) describe conjugates carrying two distinct oligonucleotide payloads — e.g., siRNA targeting DMPK combined with an ASO correcting a secondary splicing defect — within a single anti-TfR1 antibody scaffold. Separately, signals in the dataset suggest investigation of alternative muscle-expressed receptors (e.g., integrin α7β1, dystroglycan) as antibody arm targets, potentially diversifying the delivery platform beyond TfR1 and reducing competition with erythroid TfR1 biology. Use PatSnap IP analytics to monitor these emerging claims.
Dual-payload · Alternative receptor arms — preclinicalFrom GLP Toxicology to Phase 1/2 Trials: AOC Translational Readouts
Retrieved patent language and literature abstracts provide the following translational signals for AOC 1001 and AOC 1044.
| Compound | Target / Disease | Trial | Translational Signal | Biomarker |
|---|---|---|---|---|
| AOC 1001 | DMPK / DM1 | MARINA Ph 1/2 | 13-week GLP tox in cynomolgus monkeys; GLP PK/PD measuring DMPK mRNA reduction in quadriceps, tibialis anterior, and heart | MBNL1-dependent splicing ratios (CLCN1, BIN1) in muscle biopsy |
| AOC 1044 | DMD Exon 44/45 / DMD | FORTITUDE Ph 1/2 | Dose-dependent exon 44/45 skipping via RT-PCR and Western blot in mdx and hDMD/mdx transgenic mice; dystrophin restoration in skeletal and diaphragm muscle | Dystrophin protein by Western blot; creatine kinase (CK) |
Track MARINA and FORTITUDE Trial Biomarker Data
PatSnap Eureka aggregates clinical signals, patent claims, and literature endpoints in one searchable platform.
IP Concentration, Platform Extensibility & Competitive Risks
Retrieved patent and literature signals surface four strategic dimensions relevant to the Novartis–Avidity acquisition and the broader muscle-targeted siRNA competitive landscape.
IP Concentration Risk
In this dataset, Avidity Biosciences holds essentially all composition-of-matter claims for anti-TfR1 AOCs. The Novartis acquisition consolidates this IP under a single large-pharma entity, raising freedom-to-operate concerns for any competitor attempting to develop TfR1-targeted oligonucleotide conjugates in muscle disease. Monitor competitive filings via PatSnap IP analytics.
Delivery Platform Extensibility
The anti-TfR1 AOC architecture is modality-agnostic at the payload level — retrieved results show it has been applied to siRNA, ASO, and potentially splice-switching oligonucleotides. This creates a platform asset with applicability across multiple muscle diseases beyond DMD and DM1, including facioscapulohumeral muscular dystrophy and limb-girdle muscular dystrophies, which Novartis could exploit for pipeline expansion. PatSnap customers use this type of landscape analysis to identify white spaces.
Who Owns the AOC IP? Key Assignees & Academic Contributors
In this dataset, the dominant patent assignee is Avidity Biosciences (San Diego, CA, USA), which holds the most concentrated cluster of AOC composition-of-matter and method-of-use patents. The retrieved dataset reflects a commercially IP-intensive field rather than an open academic one, consistent with the stage of development. Patent activity is predominantly US-jurisdiction, with PCT filings (WO series) extending into Europe (EP), Japan, and Australia, indicating broad international IP prosecution consistent with a global commercial program.
Novartis AG appears in the dataset primarily in the context of the acquisition rationale and prior RNA therapeutics programs — notably inclisiran, a GalNAc-siRNA for PCSK9 in liver — providing precedent for the AOC delivery paradigm as an extension of established Novartis RNAi infrastructure. The WIPO PCT database confirms the international prosecution strategy for Avidity's foundational AOC families.
Academic and clinical research contributors identified in retrieved literature include Charles Thornton (University of Rochester) on DMPK biology and DM1 natural history; Annemieke Aartsma-Rus (Leiden University Medical Center) on exon skipping ASO design; and Eric Wang (University of Florida) on MBNL1 splicing regulation in DM1. The ClinicalTrials.gov registry documents the MARINA and FORTITUDE trial designs incorporating these academic biomarker frameworks.
Novartis–Avidity siRNA Platform — Key Questions Answered
The AOC (antibody–oligonucleotide conjugate) architecture links a monoclonal antibody targeting a muscle-expressed cell-surface receptor to a chemically modified siRNA or ASO payload via a cleavable or stable linker. Avidity Biosciences holds essentially all composition-of-matter claims for anti-TfR1 AOCs, making the acquisition a consolidation of this IP under Novartis for pipeline expansion across multiple muscle diseases.
TfR1 (transferrin receptor 1) is a type II transmembrane glycoprotein highly expressed on skeletal and cardiac myocytes and erythroid progenitors. The antibody arm of the AOC engages TfR1, triggering receptor-mediated endocytosis that internalizes the conjugate. Endosomal acidification and/or linker cleavage then releases the oligonucleotide payload intracellularly, achieving 10–50-fold greater muscle accumulation compared to unconjugated siRNA in rodent and primate studies.
DM1 is caused by a CTG trinucleotide repeat expansion in the 3′ UTR of the DMPK gene. Expanded CUG repeat RNA transcripts sequester the splicing regulator MBNL1 in nuclear foci, causing widespread alternative splicing dysregulation. siRNA-mediated DMPK mRNA silencing reduces toxic RNA foci and liberates MBNL1 for normal splicing activity. Sustained DMPK knockdown in DM1 patient myotubes rescues MBNL1-dependent splicing of CLCN1, BIN1, and TNNT3.
AOC 1001 targets DMPK for DM1 and has entered Phase 1/2 clinical evaluation (MARINA trial). Patent language in Avidity's 2022–2023 filings references IND-enabling studies including repeat-dose 13-week GLP toxicology in cynomolgus monkeys and GLP pharmacokinetic/pharmacodynamic studies measuring DMPK mRNA reduction in quadriceps, tibialis anterior, and heart. AOC 1044 targets DMD exon skipping and is mentioned in the context of the FORTITUDE trial, with proof-of-concept dystrophin restoration demonstrated in mdx and hDMD/mdx transgenic mouse models.
Unlike PMO-based exon skipping approaches such as eteplirsen, golodirsen, and viltolarsen, which show limited cardiac delivery, retrieved results indicate AOC-mediated cardiac muscle exposure at therapeutically relevant doses. Since TfR1 is also expressed on cardiomyocytes, AOC delivery achieves cardiac biodistribution in addition to skeletal muscle — a potential label differentiator in DMD where cardiomyopathy is the leading cause of mortality.
In this dataset, Avidity Biosciences holds essentially all composition-of-matter claims for anti-TfR1 AOCs. The Novartis acquisition consolidates this IP under a single large-pharma entity, raising freedom-to-operate concerns for competitors attempting to develop TfR1-targeted oligonucleotide conjugates in muscle disease. Retrieved results also reference lipid nanoparticle formulations and GalNAc-muscle conjugate programs at competing organizations, suggesting TfR1-AOC does not have an uncontested moat.
Still have questions about AOC patents, DMPK biology, or the competitive landscape? Let PatSnap Eureka answer them.
Ask PatSnap Eureka About AOC TherapeuticsAccelerate Your RNA Therapeutics Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map AOC patent landscapes, track DMPK and dystrophin targets, and monitor clinical biomarker signals in DMD and myotonic dystrophy.
References
- Compositions and methods for treatment of muscle disease — Avidity Biosciences, 2022, US [Patent]
- Antibody-oligonucleotide conjugates targeting DMPK for myotonic dystrophy — Avidity Biosciences, 2023, US [Patent]
- DMPK silencing by RNA interference reverses myotonic dystrophy splicing defects in patient-derived cells — Wheeler et al., 2022 [Paper]
- Antibody-siRNA conjugates for targeted delivery to skeletal and cardiac muscle — Avidity Biosciences, 2022, US [Patent]
- Anti-transferrin receptor antibody conjugated to oligonucleotides for muscle delivery — Avidity Biosciences, 2021, US [Patent]
- Targeted delivery of oligonucleotides to skeletal muscle via transferrin receptor 1 — Bhatt et al., 2023 [Paper]
- Exon skipping using antisense oligonucleotides in Duchenne muscular dystrophy — Aartsma-Rus et al., 2021 [Paper]
- Anti-TfR1 antibody engineering for reduced effector function in oligonucleotide conjugates — Avidity Biosciences, 2022, US [Patent]
- siRNA sequences targeting DMPK CTG repeat expansion for myotonic dystrophy treatment — Avidity Biosciences, 2023, US [Patent]
- Oligonucleotide conjugates for dystrophin exon skipping in DMD — Avidity Biosciences, 2023, US [Patent]
- Muscle-targeted oligonucleotide delivery platform — PCT family — Avidity Biosciences, 2021, PCT/US [Patent]
- Clinical translation of AOC-1001 for myotonic dystrophy: biomarker-driven trial design — Thornton et al., 2023 [Paper]
- Combination of dystrophin restoration and myostatin silencing via AOC platform in DMD — Avidity Biosciences, 2023, US [Patent]
- WIPO — PCT Patent Database — World Intellectual Property Organization [External source]
- NIH — National Institutes of Health — Research funding and publications in neuromuscular disease [External source]
- ClinicalTrials.gov — MARINA and FORTITUDE trial registry records [External source]
- FDA — U.S. Food and Drug Administration — Approved DMD exon skipping therapies (eteplirsen, golodirsen, viltolarsen) [External source]
- Leiden University Medical Center (LUMC) — Aartsma-Rus lab: exon skipping ASO design in DMD [External source]
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within the retrieved dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.